Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.21 | N/A | -0.15% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.21 | N/A | -0.15% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was cautious, reflecting uncertainty in market conditions. They did not provide any forward guidance during the call.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in the current market environment.
Repligen Corp's earnings report indicates a slight miss on EPS, which contributed to a 1.61% decline in stock price. The lack of revenue data and forward guidance may raise concerns among investors about the company's outlook. Management's cautious tone suggests they are navigating challenges in the market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MEDTRONIC PLC
Feb 19, 2019